Evoke Pharma Has Been Granted A Notice Of Allowance From The U.S. Patent And Trademark Office For Patent Application Pertaining To Gimoti, FDA-Approved Nasal Formulation Of Metoclopramide; The Patent Will Cover The Intranasal Pharmaceutical Composition
Portfolio Pulse from Benzinga Newsdesk
Evoke Pharma has received a Notice of Allowance from the U.S. Patent and Trademark Office for a patent application related to Gimoti, an FDA-approved nasal formulation of Metoclopramide. The patent will cover the intranasal pharmaceutical composition.
September 14, 2023 | 12:40 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Evoke Pharma's patent approval for Gimoti could potentially strengthen its market position and increase its revenue in the future.
The approval of the patent for Gimoti by the U.S. Patent and Trademark Office could potentially give Evoke Pharma a competitive edge in the market. This could lead to increased sales and revenue for the company, positively impacting its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100